LABORATORY NEWS
-
Re:Cognition Health Delivers Landmark International Clinical Trial To Explore Whether A Simple Finger-Prick Blood-Based Biomarker Test Can Provide Earlier Alzheimer's Diagnosis
Re:Cognition Health, a global leader in new treatments for Alzheimer's Disease, is delivering an international clinical trial to evaluate whether a simple finger-prick blood test can revolutionize how Alzheimer's disease is diagnosed.
- Cepheid And Oxford Nanopore Expand Partnership Following Successful Phase One Collaboration
- Waters Announces CE Mark For Next-Generation Fully Automated BD BACTEC FXI Culture System For Bloodstream Infection Diagnosis
- QIAGEN Expands Into Bloodstream Infection Syndromic Testing With New Rapid QIAstat-Dx Panel
- Labcorp Introduces AI-Powered Real-World Data Platform With AWS And Datavant To Accelerate Alzheimer's Research
ARCHIVED NEWSLETTER
- 04.07.26 -- Navigating GMP Biosafety Challenges In ATMP Manufacturing
- 02.24.26 -- Rethinking Disease Modification Through Targeted Immunotherapy
- 02.10.26 -- Why Use Total Organic Carbon Analysis For Cleaning Validation?
- 01.20.26 -- Rats Behind The Wheel: The Right Preclinical Way To Investigate Drug Effects On Driving?
- 01.06.26 -- To Fight Cancer, Gene Editing Needs To Solve Its Delivery Problem